Modern Alzheimer’s Treatments Offer Hope with Disease-Modifying Therapies

For decades, Alzheimer’s disease research focused on managing symptoms. Now, a new wave of therapies is emerging that aims to modify the disease’s course, offering a glimmer of hope for the millions affected by this devastating condition. These advancements, including antibody therapies and innovative cellular approaches, represent a significant shift in how we approach Alzheimer’s treatment.

Understanding the New Approaches

Traditionally, Alzheimer’s treatments focused on temporarily alleviating symptoms like memory loss and cognitive decline. However, these treatments did not address the underlying pathology of the disease. The latest breakthroughs target the fundamental mechanisms driving Alzheimer’s, specifically the buildup of amyloid plaques and tau tangles in the brain.

Targeting Amyloid Plaques

A key strategy involves removing amyloid beta, a protein that clumps together to form plaques. These plaques are believed to play a crucial role in the development of Alzheimer’s. Lecanemab (Leqembi®), an antibody therapy, has received traditional FDA approval to treat early Alzheimer’s disease. It works by targeting and removing these beta-amyloid plaques from the brain. Leqembi is administered via intravenous (IV) infusion and is intended for individuals with mild cognitive impairment (MCI) or mild dementia who have confirmed elevated beta-amyloid levels.

Clinical trials have shown that Lecanemab can sluggish cognitive and functional decline, potentially allowing individuals to maintain independence for a longer period. However, it’s vital to note that it is not a cure and comes with potential risks, necessitating careful consideration and discussion with a healthcare provider.

Another traditionally approved treatment, donanemab (Kisunla®), also targets amyloid plaques.

Beyond Plaque Removal: A New Cellular Immunotherapy

Recent research at Washington University School of Medicine in St. Louis has explored a novel approach using cellular immunotherapy. Researchers engineered astrocytes – brain cells – to act as “super cleaners,” removing damaging proteins like amyloid beta. This approach, similar to CAR-T cell therapy used in cancer treatment, involves equipping astrocytes with a CAR homing device to target amyloid plaques.

In studies with mice, a single treatment with these engineered astrocytes reduced amyloid plaque levels by half. While still in early stages, this research suggests a potential for a more efficient and less frequent treatment option compared to current antibody therapies.

Why Previous Approaches Faced Challenges

Earlier attempts to target amyloid plaques, such as aducanumab, faced setbacks and ultimately led to the drug being withdrawn from the market. Research suggests that simply removing amyloid plaque may not be enough to halt the progression of Alzheimer’s, indicating the disease is more complex than initially understood.

The Future of Alzheimer’s Treatment

The development of disease-modifying therapies like Lecanemab and the promising results from cellular immunotherapy represent a turning point in Alzheimer’s research. While challenges remain, these advancements offer renewed hope for individuals and families affected by this disease.

Frequently Asked Questions

• Is there a cure for Alzheimer’s? No, currently there is no cure for Alzheimer’s disease. However, new treatments like Lecanemab are designed to modify the disease’s progression.
• What are the side effects of these new treatments? Like all medications, these treatments can have side effects. It’s crucial to discuss the potential benefits and risks with your healthcare provider.
• Who is eligible for these treatments? Currently, treatments like Lecanemab are approved for individuals in the early stages of Alzheimer’s disease with confirmed amyloid plaque buildup.

For more information and support, contact the Alzheimer’s Association 24/7 Helpline at 800.272.3900.